Rznomics Inc. continued South Korea’s year-end biotech rally with a ₩46.35 billion (US$31.35 million) IPO Dec. 18. Proceeds will fund Seongnam-si, South Korea-based Rznomic’s pipeline of gene therapies, built on the company’s trans-splicing ribozyme RNA Replacement Enzyme technology platform.
Biopharmas in Asia-Pacific raising money in public or private financings: Allink Biotherapeutics, Orum Therapeutics, Rezubio, Syremis Therapeutics, Syneron.
RSS
